What Veterans Need to Know

The Department of Veterans Affairs began enrolling veterans in its first-ever clinical trial of therapy assisted by MDMA, or Ecstasy, in May 2026.

The program targets treatment-resistant PTSD and alcohol use disorder. The announcement did not come with a major press rollout. But for veterans who have cycled through medication management, group therapy, prolonged exposure, cognitive processing therapy and residential programs — and are still struggling — it landed anyway.

The trial is real, and it is a meaningful step. It is also, by design, small, tightly controlled, and years away from producing results. Veterans reading about it should understand both of those things at once.

What the VA’s MDMA Trial Is

The VA trial, registered at ClinicalTrials.gov as NCT0711883, is formally titled “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in U.S. Veterans.” Enrollment began May 18, 2026. The study is led by Dr. Erica M. Eaton at the Providence VA Medical Center in Rhode Island, with a second site at the VA Connecticut Healthcare System in West Haven.

Approximately 80 veterans will be enrolled. The design is randomized and placebo-controlled, meaning participants are randomly assigned to receive either MDMA-assisted therapy or an identical structured therapy session with an active placebo. The double-blind structure is specifically what the FDA said it needed before it would reconsider MDMA therapy for PTSD after declining to approve it in August 2024.

The trial targets a population the VA’s existing treatment menu has not served well: veterans with severe PTSD and a co-occurring alcohol use disorder. Both conditions must be present. Both must be treatment-resistant. Results are expected in May 2030. The trial is part of a broader VA psychedelic research initiative supported by more than $23 million in external grants across 19 active studies, further accelerated by President Trump’s April 2026 executive order directing federal agencies to fast-track psychedelic therapy research and allocating $50 million through ARPA-H for state programs.

Read More: Ibogaine, LSD and Psilocybin: Trump’s New Order a Medical ‘Turning Point’

Why Veterans — and Why It Matters

The dual diagnosis of PTSD and alcohol use disorder is not unusual in the veteran population. It is common, and VA’s traditional approach to it has been imperfect. Benjamin Krause, a disabled Air Force veteran, VA-accredited attorney and founder of DisabledVeterans.org who represents veterans in complex benefits appeals, has worked with this population for years and describes a systemic pattern.

“VA is better than it used to be at recognizing co-occurring PTSD and substance-use disorders, but veterans still run into a stigma problem,” Krause said. “Too often, alcohol use is treated as a separate behavioral failure instead of being understood as part of the PTSD picture.”

Krause said the design of the trial reflects that clinical reality more honestly than most research does: “The fact that this trial is focused on both severe PTSD and alcohol use disorder is important because that reflects the real-world veteran population far better than a clean, simplified diagnosis on paper.”

What drives veterans to seek alternatives in the first place is not novelty. It is exhaustion, Krause said. “What I hear from veterans is not usually, ‘I want something trendy,’ It is more often, ‘I cannot sleep, I cannot stay employed, my marriage is falling apart, I am drinking to shut my mind off, and the standard approach has not gotten me stable.'”

What a Prior FDA Rejection Meant and Why the VA Trial Is Designed the Way It Is

In August 2024, the FDA declined to approve MDMA-assisted therapy for PTSD, citing concerns about trial design, the durability of treatment benefits, and safety data from prior studies. The agency indicated it would need a new randomized, placebo-controlled study before reconsidering. The VA trial is built to answer that requirement directly.

“It means VA is trying to generate evidence that can survive regulatory scrutiny. That matters. MDMA is not approved for PTSD, and enthusiasm alone cannot create a lawful clinical pathway,” Krause said. “Building to FDA specifications should mean tighter controls, clearer protocols, better documentation, stronger safety monitoring, and a more credible result. A weak trial can actually set the field back.”

The broader context includes the fact that 31 bipartisan House members, including Reps. Dan Crenshaw (R-Texas) and Alexandria Ocasio-Cortez (D-New York), urged FDA Commissioner Martin Makary in May 2026 to expedite the MDMA therapy review. The Disabled American Veterans also weighed in, saying that “far too many veterans continue to struggle with the invisible wounds of war, often after exhausting traditional treatment options.”

What 80 Participants and 2030 Mean for Veterans Today

The scale of the trial is significant. Eighty veterans across two sites is not an access solution. It is an evidence-building step — and that distinction matters for veterans who may be hoping the trial represents an opening to treatment soon.

“An 80-person trial is meaningful as a research step, but it is obviously tiny compared to the national treatment gap. This is not VA opening the door for widespread MDMA treatment,” Krause said. “It is VA testing whether this approach can be studied safely and credibly in a veteran population with complex needs. If the results are positive, the next questions will be replication, scale, provider training, risk protocols, funding, and how VA would deliver this safely across a national health system.”

Even a positive result in 2030 would not immediately translate to widespread availability. Krause outlines what would realistically follow: further FDA action, possible DEA scheduling changes, VA clinical guidance development, provider training, site certification, eligibility standards, and integration with existing PTSD and substance-use care programs.

“A positive trial would be a major step, but it would not be the finish line,” Krause said. “It would start the next phase: turning research into a safe, lawful, scalable treatment model inside one of the largest health systems in the country.”

What Veterans Seeking Alternatives Should Know Now

Veterans are already seeking psychedelic therapies outside the VA system, in states where psilocybin is legal, through private clinics and, in some cases, through unregulated channels. Krause is direct about the risks.

“I counsel caution. Veterans need to understand the legal risk, medical risk, medication-interaction risk, trauma risk and continuity-of-care risk,” Krause said. “Underground or overseas treatment may not include proper screening, emergency support, psychiatric follow-up, or coordination with the veteran’s existing providers. That matters, especially for veterans with severe PTSD, suicidal ideation, alcohol use disorder, heart issues or complex medication histories.”

He also acknowledges that the demand for alternatives is not irrational: “I do not shame veterans for looking. The demand exists because many people are suffering and do not feel helped by standard care.”

But he is clear about the hierarchy: Speak with qualified medical professionals; avoid unsupervised or illegal use; keep treating providers informed; and pursue lawful clinical trials or regulated options when available.

From a VA claims standpoint, Krause notes that treatment resistance itself has relevance even while waiting for a clinical pathway.

“Veterans should continue documenting symptoms, treatment failures, functional impairment, and secondary conditions,” he said. “Even if a clinical pathway for MDMA does not exist yet, the treatment gap itself may be highly relevant to a veteran’s disability claim, employability and need for additional support.”

What Veterans Should Take Away

“The most important thing is this: The trial is a serious step, but it is not a shortcut,” Krause said. “Veterans should be hopeful that VA is finally studying treatments that many veterans have been asking about for years, but they should also understand that MDMA is not presently an approved PTSD treatment, and this trial will not create immediate access for most veterans. Do not wait until 2030 to seek help.”

Veterans whose PTSD is not improving should talk to their providers, document what has and has not worked, seek support for alcohol use or other co-occurring conditions, and consider lawful clinical trials where appropriate. Veterans interested in participating in the VA MDMA trial can find information at ClinicalTrials.gov by searching NCT0711883. Military.com will report on the trial’s progress as results become available.

Veterans in crisis can reach the Veterans Crisis Line at any time by calling 988 and pressing 1, texting 838255, or chatting at VeteransCrisisLine.net.

About the Expert

Benjamin Krause is a disabled U.S. Air Force veteran, VA-accredited attorney and investigative journalist. After litigating his own benefits from a 10 percent rating to 100 percent permanent and total, he founded Krause Law, PLLC, representing veterans nationwide in complex benefits appeals, and DisabledVeterans.org, where he has published more than 2,000 investigative articles. His reporting has appeared in Newsweek, CBS Evening News, Stars and Stripes, and The Hill. He was named 2025 Minnesota Vetrepreneur of the Year.